Business Wire

HemoSonics Registers CE Mark for its New QStat® Cartridge, Expanding the Use of its Innovative Quantra® Hemostasis System to Trauma Surgery and Liver Transplant Settings

10.9.2019 23:35:00 EEST | Business Wire | Press release

Share

HemoSonics is excited to announce that its new QStat Cartridge, an extension of its groundbreaking Quantra Hemostasis System, has registered for CE Mark and is now commercially available in Europe and Hong Kong. The utility of the Quantra System, which was previously available with the QPlus Cartridge for cardiovascular and major orthopedic surgeries, is now expanded with the addition of the QStat Cartridge and can now be used across the hospital in trauma surgery and liver transplant settings. The Quantra System provides rapid, actionable coagulation results at the point of care, giving clinicians the opportunity to make informed bleeding management decisions when time is critical.

Improving patient outcomes and facilitating goal-directed therapy is the primary focus of any diagnostic system. But the new Quantra System is breaking new ground in point-of-care viscoelastic testing (VET) efficiency by combining rapid time to results, clear outputs, and a simple intuitive design. SEER (Sonic Estimation of Elasticity via Resonance) Sonorheometry, the revolutionary ultrasound technology, is the foundation of this remarkably efficient and reliable analyzer, which now offers an expanded menu of whole-blood tests in two self-contained cartridges; QPlus® for cardiac and major orthopedic surgery, and QStat for trauma and liver transplant surgery.

The QStat Cartridge is a fully sealed, room-temperature stable, disposable cartridge that offers a panel of viscoelastic coagulation tests, including Clot Time (CT), Clot Stiffness (CS), Fibrinogen Contribution to Clot Stiffness (FCS), Platelet Contribution to Clot Stiffness (PCS), and Clot Stability to Lysis (CSL). All tests except the latter take 25 minutes or less to produce valid results (typically 12-15 minutes), whereas the clot lysis test (CSL) is enabled to run for up to 60 minutes. The Quantra System requires less than 60 seconds of operator’s hands-on time – and requires no pipetting or wait time after draw. Results are provided on an easy-to-read, user-friendly “dials” interface that does not require extensive training.

Studies have demonstrated strong correlation between the Quantra System and both standard laboratory tests and other viscoelastic hemostasis assays. In addition, the QStat Cartridge provides novel parameters designed specifically to give clear actionable information in critical care settings. The Quantra System reports both fibrinogen (FCS) and platelet contributions (PCS) to clot stiffness, giving clinicians the opportunity to quickly consider the most appropriate therapies to apply when bleeding is a concern. The Clot Stability to Lysis (CSL) test provides an adaptive and confirmatory result based on the level and onset time of clot lysis. Additionally, the Quantra QStat System directly analyzes and compares changes in clot stiffness in both the presence and absence of tranexamic acid, thus automatically correcting for potentially confounding results inherent to earlier VET systems.

“Trauma and liver surgeries pose an enormous risk of acute bleeding,” said Timothy J. Fischer, President and Chief Executive Officer of HemoSonics. “The Quantra QStat System is a breakthrough in point-of-care bleeding management because it provides rapid, reliable, and novel information to aid clinicians in their decision making in the ER, trauma bay, or post-operative ICU. What makes the new QStat Cartridge unique is its unparalleled ease of use and its innovative coagulation tests for critical injury and liver transplant, including Platelet Contribution to Clot Stiffness and Clot Stability to Lysis.”

Availability
The Quantra Hemostasis System, including QPlus and QStat Cartridges and 2 levels of external quality controls, is commercially available in countries within Europe.

In the United States, the Quantra Hemostasis Analyzer, QPlus Cartridge and associated external quality controls comprise the Quantra® QPlus® System which received de novo marketing authorization by the FDA in March of 2019. In the United States the QStat Cartridge is available for investigational use only.

About HemoSonics
HemoSonics is a medical device company with the primary mission to deliver clinical tools that provide actionable information in the critical care settings; resulting in better care for patients and lower overall medical costs.

The Quantra Hemostasis Analyzer, the flagship product of HemoSonics, is designed to improve patient outcomes and reduce healthcare costs by providing unique and optimized coagulation information, for easy and fast interpretation and simple, more efficient point-of-care bleeding management workflows.

HemoSonics is headquartered in Charlottesville, VA, with research, development and manufacturing facilities in Durham, NC. For more information, visit www.hemosonics.com.

HemoSonics is part of the Stago group, a leading company in the in vitro Diagnostics industry dedicated to the exploration of thrombosis and hemostasis.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lee DeGeer
Chief Commercial Officer
(919) 504-1030
contact@hemosonics.com
HemoSonics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Helical Fusion Awarded Up to JPY 19.2 Billion in Japanese Government Funding to Accelerate Commercial Fusion Power18.11.2026 14:36:00 EET | Press release

Helical Fusion Co., Ltd., a fusion energy company developing commercially viable power plants based on Helical Stellarator technology, has been formally selected for a major Japanese government grant program administered by the Ministry of Economy, Trade and Industry (METI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118128278/en/ The maximum government subsidy is approximately JPY 19.2 billion (USD 126 million). The grant-supported project is scheduled to run through February 2029. Through the Helix Program, Helical Fusion leads overall plant design and systems integration, drawing on research from Japan’s national research institutions and the engineering and manufacturing expertise of approximately 40 companies in Japan. The program aims to turn Japan’s scientific and industrial strengths into practical fusion power. The funding will accelerate three areas of development: Helix HARUKA: Manufacturing and assembly of

New TOURISE Report Reveals How Traveler Expectations Are Changing the Rules for Global Tourism18.11.2026 14:00:00 EET | Press release

Changing traveler priorities are reshaping global tourism, influencing where people go, how they spend and what they value most from their journeys. A new report released by TOURISE, The Future Traveller, explores these shifts and what they mean for the industry through 2030. Developed in collaboration with Euromonitor International, the report draws on consumer surveys and perspectives from industry leaders. The report finds that travel decisions are increasingly shaped by the priorities and circumstances of each trip, rather than demographics alone. It calls on destinations and businesses to rethink how they attract visitors and measure success, shifting the focus from high-spending travelers to high-value trips that deliver meaningful experiences, support local economies and create lasting benefits for communities. “Travelers are not making decisions as fixed demographic segments. They are responding to purpose, pressures and possibilities of each trip,” said His Excellency Ahmed Al

Grand Prix ACF AutoTech 2027: Applications Open for the 10th Edition18.11.2026 14:00:00 EET | Press release

The Automobile Club de France (ACF) and ESSEC Alumni are launching the 10th edition of the Grand Prix ACF AutoTech, the leading competition for automotive and mobility startups. French and international startups can apply until November 27, 2026 at 11:59 p.m. (CET) at www.grandprixacfautotech.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118772168/en/ Jury members and former finalist startups for the launch of 10th Edition of Grand Prix ACF AutoTech (c) Quentin Vaquez Since 2018, the competition has selected 52 finalists, including Chargemap, Hiflow, ChargeGuru and Geolith, who have together raised more than €700 million. Only 6 have failed: a survival rate of nearly 90%. The 2026 edition rewarded Altrove (Grand Prix ACF), Bloomineral (ACF Pioneer Prize and GreenTech Mention) and IoT.bzh (Industrialization Prize). “Ten editions is an achievement we are proud of. The number of applications, rising every year, shows h

Rockwell Automation Signs Definitive Agreement to Acquire AGILOX18.11.2026 14:00:00 EET | Press release

Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced it has signed a definitive agreement to acquire Austria-based AGILOX, a maker of high-end autonomous mobile robots (AMRs) that are driven by self-developed artificial intelligence and swarm networking technology. Together, AGILOX’s proven forklift AMR portfolio and OTTO by Rockwell Automation’s flatbed AMR platform will create a comprehensive autonomous material movement offering, elevating AGILOX from a best-in-class point solution to a cornerstone of a world-class comprehensive production logistics capability. The acquisition will combine OTTO's strong presence in North America with AGILOX's established footprint across Europe. AGILOX will gain access to Rockwell's deep customer relationships in strategic verticals like consumer packaged goods and life sciences. The acquisition will create a stronger partner ecosystem and more than double R

Ant International Pioneers PayNow Deep-Linking for E-Commerce, Explores Government Services Use Case Under MAS’ PayNow Gen2 Initiative18.11.2026 13:40:00 EET | Press release

Ant International is the first partner under the Monetary Authority of Singapore (MAS)’s PayNow Generation 2.0 launch to introduce live use cases for deep-linking for e-commerce and digital government services. The launch is enabled by Antom, its global merchant payment and digitisation services provider, and Antom’s Southeast Asia subsidiary, 2C2P by Antom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118384895/en/ At the Singapore Fintech Festival 2026, MAS announced phase 2 of the PayNow Gen2 report, a joint study by the Association of Banks in Singapore (ABS) and the MAS to define the next wave of innovation for Singapore's instant payments system. “PayNow Gen2 marks another important step in Singapore’s journey towards a more innovative, connected and future-ready payments ecosystem," said Gary Liu, Chief Executive Officer of Antom and Senior Vice President of Ant International. “At Ant International, we believe th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye